Heres What Research Shows As GLP-1 receptor agonists like semaglutide have gained widespread use for weight management, questions about their long-term safety have become increasingly important
Maximum weight loss (20%+ body weight) Achieving 20 percent or greater weight loss consistently requires the higher dose levels of 10mg to 15mg weekly, maintained over nine months to a year or longer
How long does it take for semaglutide to kick in
Mounjaro (tirzpatide) : double agoniste GLP-1/GIP, -20,9 % de poids (SURMOUNT-1) mdicament autoris, rembours sous conditions ds le 15 juin 2026 Retatrutide : triple agoniste GLP-1/GIP/glucagon, -28,3 % 80 semaines (TRIUMPH-1, phase 3) molcule de recherche, non commercialise avant ~2028 cart d'environ +7 +8 points en faveur du retatrutide, en comparaison indirecte (aucun essai tte--tte) Retatrutide vs Mounjaro : la rponse directe En comparaison indirecte des essais pivots, le retatrutide dpasse le Mounjaro sur la perte de poids : -28,3 % (TRIUMPH-1, 12 mg, 80 semaines) contre -20,9 % pour le tirzpatide (SURMOUNT-1, 15 mg, 72 semaines), soit environ +7 +8 points
Even when weight-loss therapies improve the apnea-hypopnea index, some patients may continue to experience clinically significant breathing disruptions during sleep, he says
